Additionally, previous studies have reported that the efficacy of PD‐L1 blockade in myeloma patients is limited.[33] One possible reason is that some myeloma patients have low expression levels of PD‐L1 on their tumor cells, rendering them insensitive to PD‐L1 antibody therapy. Here, CD274 is linked to neoplasm.